Core Insights - Flare Therapeutics has entered a clinical trial collaboration with Merck to evaluate FX-909 in combination with KEYTRUDA for advanced urothelial cancer [1][2] - FX-909 is a first-in-class small molecule inhibitor targeting PPARG, showing clinical proof of concept as a monotherapy [2][3] - The combination study aims to investigate safety, tolerability, immunologic effects, and preliminary efficacy in patients with advanced urothelial carcinoma [2] Company Overview - Flare Therapeutics is focused on drugging transcription factors to unlock therapeutic potential, with FX-909 as its lead program for locally advanced or metastatic urothelial cancer [3] - The company is also developing FX-111, a selective degrader for the androgen receptor, targeting metastatic castration-resistant prostate cancer [3] - Flare Therapeutics utilizes an integrated discovery platform to identify novel ligands for previously undrugged targets [3]